Drug assessment by a Pharmacy and Therapeutics committee: from drug selection criteria to use in clinical practice

References

• HartmanMMartinABBensonJCatlinANational health spending in 2011: overall growth remains low, but some payers and services show signs of accelerationHealth Aff (Millwood)2013321879923297275
   PubMed Web of Science ®Google Scholar
• RamliAAljunidSMSulongSMd YusofFANational Drug Formulary review of statin therapeutic group using the multiattribute scoring toolTher Clin Risk Manag2013949150424353428
   PubMed Web of Science ®Google Scholar
• ZhangYSoumeraiSBDo newer prescription drugs pay for themselves? A reassessment of the evidenceHealth Aff (Millwood)200726388088617485770
   PubMed Web of Science ®Google Scholar
• [No authors listed]New drugs and indications in 2012. Sluggish progress, timid measures to protect patientsPrescrire Int20132213710510723662323
   PubMedGoogle Scholar
• Directive 2004/27/EC of the European Parliament and the Council of March 31, 2004 amending Directive 2001/83/EC on the Community code relating to medicinal products for human use (Text with EEA relevance), 2004Official Journal L136, 30/4/200420042683457 Available from: http://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri=CELEX:32004L0027:EN:HTMLAccessed February 15, 2014
   Google Scholar
• PignattiFGravanisIHeroldRVamvakasSJonssonBMartyMThe European Medicines Agency: an overview of its mission, responsibilities, and recent initiatives in cancer drug regulationClin Cancer Res201117165220522521844037
   PubMed Web of Science ®Google Scholar
• Soto AlvarezJTherapeutic and social usefulness of medicines: how can it be evaluated and quantified?Med Clin (Barc)20091323104105 Spanish19211062
   PubMed Web of Science ®Google Scholar
• FullertonDSPAtherlyDSFormularies, therapeutics, and outcomes: new opportunitiesMed Care200442Suppl 4III39III4415026670
   PubMed Web of Science ®Google Scholar
• DrummondMFMasonAREuropean perspective on the costs and cost-effectiveness of cancer therapiesJ Clin Oncol200725219119517210939
   PubMed Web of Science ®Google Scholar
• McCabeCBergmannLBosanquetNMarket and patient access to new oncology products in Europe: a current, multidisciplinary perspectiveAnn Oncol200920340341218854550
   PubMed Web of Science ®Google Scholar
• SmithTJHillnerBEBending the cost curve in cancer careN Engl J Med2011364212060206521612477
   PubMed Web of Science ®Google Scholar
• Group for Innovation Assessment Standardisation and Research in the Selection of Drugs (GENESIS) of the Spanish Association of Hospital PharmacyMADRE Programme. Procedures Manual. PDF 3.0 version2005 Available from: http://gruposdetrabajo.sefh.es/genesis/index.php?option=com_content&view=article&id=11&Itemid=13Accessed February 15, 2014
   Google Scholar
• García RobredoBCalleja HernándezMALuque VegaMIUbago PérezRFaus DáderMJCompliance of prescriptions for chronic obstructive pulmonary disease patients given upon hospital dischargeFarm Hosp2010344188193 Spanish20537931
   PubMedGoogle Scholar
• R Core TeamR: A language and environment for statistical computingR Foundation for Statistical ComputingVienna, Austria Available from: http://www.R-project.org/Accessed February 15, 2014
   Google Scholar
• WHO Collaborating Centre for Drug Statistics MethodologyGuidelines for ATC classification and DDD assignment 2011OsloWorld Health Organization2010 Available from: http://www.whocc.no/filearchive/publications/2011guidelines.pdfAccessed June 25, 2014
   Google Scholar
• PuigventósFSantos-RamosBOrtegaADurán-GarcíaEStructure and procedures of the pharmacy and therapeutic committees in Spanish hospitalsPharm World Sci201032676777520820918
   PubMedGoogle Scholar
• Ortega EslavaAPuigventós LatorreFSantos-RamosBCalderon HernanzBVilanova BoltóMClassification and variability of drug assessment reports on the GENESIS group (SEFH) webpageFarm Hosp2011353140147 Spanish21450502
   PubMedGoogle Scholar
• New Medicines: 2007 ReviewInformación Terapeútica del Sistema Nacional de Salud20083211725 Available from: http://www.msssi.gob.es/va/biblioPublic/publicaciones/docs/vol32_1NuevosPrincipiosActivos2007.pdfAccessed February 15, 2014 Spanish
   Google Scholar
• New Medicines: 2008 ReviewInformación Terapeútica del Sistema Nacional de Salud20093311522 Available from: http://www.msssi.gob.es/va/biblioPublic/publicaciones/recursos_propios/infMedic/docs/vol33_1ppiosActivos.pdfAccessed February 15, 2014 Spanish
   Google Scholar
• New Medicines: 2009 ReviewInformación Terapeútica del Sistema Nacional de Salud20103411225 Available from: http://www.msssi.gob.es/va/biblioPublic/publicaciones/recursos_propios/inf-Medic/docs/BoletinVol34n1_12a25.pdfAccessed February 15, 2014 Spanish
   Google Scholar
• New Medicines: 2010 ReviewInformación Terapeútica del Sistema Nacional de Salud20113512131 Available from: http://www.msssi.gob.es/va/biblioPublic/publicaciones/recursos_propios/infMedic/docs/vol35_1_Nuevos_PA.pdfAccessed February 15, 2014 Spanish
   Google Scholar
• Puigventós LatorreFSantos-RamosBOrtega EslavaADurán-GarcíaMEVariability in activity and results from drug assessments by pharmacy and therapeutics committees in Spanish hospitalsFarm Hosp2011356305314 Spanish21497125
   PubMedGoogle Scholar
• Durán-GarcíaESantos-RamosBPuigventos-LatorreFOrtegaALiterature review on the structure and operation of Pharmacy and Therapeutics CommitteesInt J Clin Pharm201133347548321416393
   PubMed Web of Science ®Google Scholar
• HoffmannMThe right drug, but from whose perspective? A framework for analysing the structure and activities of drug and therapeutics committeesEur J Clin Pharmacol201369Suppl 1798723640192
   PubMedGoogle Scholar
• FerlayJShinH-RBrayFFormanDMathersCParkinDMEstimates of worldwide burden of cancer in 2008: GLOBOCAN 2008Int J Cancer2010127122893291721351269
   PubMed Web of Science ®Google Scholar
• US Food Drug AdministrationPostmarket Drug Safety Information for Patients and Providers. Avastin (bevacizumab information)2011 Available from: http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm193900.htmAccessed February 15, 2014
   Google Scholar
• European Medicines AgencyChanges since initial authorization of medicine. Avastin-H-C-582-II-33: EPAR Assessment Report – Variation Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Assessment_Report_-_Variation/human/000582/WC500108311.pdfAccessed February 15, 2014
   Google Scholar
• NgKZhuAXTargeting the epidermal growth factor receptor in metastatic colorectal cancerCrit Rev Oncol Hematol200865182018006328
   PubMed Web of Science ®Google Scholar
• European Medicines AgencyChanges since initial authorization of medicine. Erbitux-H-C-558-II-20: EPAR Assessment report variation Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Assessment_Report_-_Variation/human/000558/WC500029117.pdfAccessed February 15, 2014
   Google Scholar
• SullivanRPeppercornJSikoraKDelivering affordable cancer care in high-income countriesLancet Oncol2011121093398021958503
   PubMed Web of Science ®Google Scholar
• European Medicines AgencyChanges since initial authorization of medicine. Velcade-H-C-539-II-28: EPAR Assessment Report – Variation Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Assessment_Report_-_Variation/human/000539/WC500048473.pdfAccessed February 15, 2014
   Google Scholar
• TylerLSColeSWMayJRASHP guidelines on the Pharmacy and Therapeutics Committee and the formulary systemAm J Health Syst Pharm200865131272128318589893
   PubMedGoogle Scholar
• ReubenDBMorVHirisJClinical symptoms and length of survival in patients with terminal cancerArch Intern Med19881487158615913382303
   PubMed Web of Science ®Google Scholar